

JC17 Rec'd PCT/PTO 09 JUN 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KEOGH *et al.*Appl. No.: *To be assigned (U.S. Nat'l Stage
of PCT/US2003/038949; Int'l filing date: December
10, 2003)*Filed: *Herewith*For: **HLA-A1, -A2, -A3, -A24, -B7 and
-B44 Tumor Associated Antigen
Peptides and Compositions**Confirmation No.: *To be assigned*Art Unit: *To be assigned*Examiner: *To be assigned*

Atty. Docket: 2060.0150006/EKS/PAC

**Preliminary Amendment Under 37 C.F.R. § 1.115 and
Submission of Substitute Sequence Listing Under 37 C.F.R. § 1.825(a)**Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In advance of prosecution, Applicants submit the following Amendment and Remarks. In compliance with 37 C.F.R. § 1.825(a), Applicants also submit substitute sheets to amend the paper copy of the Sequence Listing. This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made;
- (C) Starting on a separate sheet, a complete listing of all of the claims:
 - in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims;
- (D) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.